C-Care and Healthcare Global Enterprises collaborate to enhance cancer care in Mauritius

New Delhi: C-Care (Mauritius) Ltd has entered into a strategic partnership with Healthcare Global Enterprises Limited (HCG). The partnership, effective from July 1, 2024, aims to enhance cancer care in Mauritius through advanced clinical services, training, and patient referrals.

Under the Memorandum of Understanding (MoU), HCG will provide clinical and outpatient consultation (OPD) services at the C-Care Cancer Center, located within C-Care Darné in Floréal. The services will be delivered by HCG’s team of oncologists specializing in various areas of cancer treatment, offering Mauritian patients access to world-class care.

The partnership is built on five key areas: cutting-edge clinical services, training and knowledge-sharing, advanced diagnostic services, facilitation of patient referrals, and a commitment to excellence. HCG will supply specialized oncologists to treat complex cancer cases, ensuring that patients receive personalized treatments backed by international expertise.

C-Care’s nuclear medicine staff will also benefit from training provided by HCG experts. This collaboration is expected to elevate the skills and knowledge of the Mauritian medical teams, ultimately improving the quality of care available to patients in the country. The agreement will allow C-Care patients to access PET scans at preferential rates through HCG, while those requiring advanced cancer treatments not available locally will be referred to HCG hospitals in India.

Raj Gore, CEO of Healthcare Global Enterprises, expressed, “HCG is delighted to partner with C-Care and extend its clinical services to patients in Mauritius. This MoU represents a shared vision of improving cancer care and making it more accessible to patients in the region. By bringing our expertise through our cutting-edge clinical and OPD services, we are committed to providing personalized, advanced and precise cancer care to the citizens of Mauritius. This collaboration will not only significantly enhance the quality of care available but also provide opportunities for C-Care’s medical team to expand their expertise through collaborative training and knowledge exchange.”

Hélène Echevin, CEO of C-Care Group, echoed these sentiments, noting, “This collaboration with HCG underlines our commitment to providing world-class healthcare to our patients. By leveraging HCG’s expertise, we aim to improve the quality of cancer care available in Mauritius and ensure that our patients have access to the best possible treatment options. This collaboration will also enable our teams to achieve a high level of quality in all aspects of cancer, even the most complex.”

With C-Care having secured all necessary government approvals, the partnership is set to ensure the seamless delivery of services and uphold the highest standards of medical care in the fight against cancer.